NCT03600233 - Study of CVM-1118 for Patients With Advanced Neuroendocrine Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 15, 2018

Primary Completion Date

September 30, 2024

Study Completion Date

December 31, 2025

Conditions

Neuroendocrine TumorsPancreatic Neuroendocrine TumorGastro-enteropancreatic Neuroendocrine TumorLung Neuroendocrine NeoplasmNeuroendocrine Carcinoma

Interventions

DRUG

CVM-1118

"Patients will initially receive CVM-1118 orally twice daily at 200 mg per dose (400 mg total daily dose).~Patients who tolerate this dose for at least 2 Cycles will have the option of increasing the dose of CVM-1118 to 300 mg BID (600 mg total daily dose) if specific criteria are met."

Trial Locations (8)

704

National Cheng Kung University Hospital, Tainan City

Unknown

Chang Gung Memorial Hospital, KaoHsiung, Kaohsiung City

Kaohsiung Medical University Hospital, Kaohsiung City

New Taipei Municipal TuCheng Hospital, New Taipei City

China Medical University Hospital, Taichung

Taichung Veterans General Hospital, Taichung

Taipei Veterans General Hospital, Taipei

Chang Gung Memorial Hospital, LinKou, Taoyuan

All Listed Sponsors

lead

TaiRx, Inc.

INDUSTRY